Ioannis Mantzaris

Improved outcomes in TP53-mutated MDS/AML without added toxicity. Metronomic decitabine /venetoclax.
Haematologica
doi.org/10.3324/haemat… @Amitvermamds @aditishasMD @YannisMantz @Saunthararajah @SteidlUli @mkonople @EinsteinMed @MontefioreNYC

Crispr modified CD70 allo CARs against T cell malignancies. Trial co-led by our outstanding Alex Sica in @TheLancetOncol @MontefioreNYC @EinsteinMed thelancet.com/journals/lanon…

🔥 Excited for our Phase 1 study Ven + 7+3 for Newly Diagnosed AML demonstrating 85% CR (86% MRD-neg) @BloodJournal @ MontefioreNYC @EinsteinMed @MontefioreNYC Eric J. Feldman @MendelGoldfing2 @mkonople @Amitvermamds @aditishasMD @Gritsman_lab #leusm doi.org/10.1182/blood.…

🔥 Our clinical trial of metronomic low-dose decitabine-ven in frontline MDS/ AML shows low tox, high efficacy & high response rate in TP53 mutant pts!! pubmed.ncbi.nlm.nih.gov/39316768/ @Amitvermamds @aditishasMD @YannisMantz @mkonople @Saunthararajah @MontefioreNYC @EinsteinMed #leusm

@TherealDoctorJ That resonates so much! Very well said! I’m sorry for your loss!

@JanakiramMurali @sghmd @jd_beckman @jmaakaron @fhemd1 @aditishasMD @jesusanampa That’s not funny 😛 I’m not a millennial 😊

Yay...... I am a geriatric Millennial. Perhaps this should be a checkbox in an application form instead of age - baby boomers, GM, gen Z @sghmd @jd_beckman @jmaakaron @fhemd1 @aditishasMD @YannisMantz @jesusanampa

@iannisaifantis1 @aditishasMD The bald and the beatiful 😉

@aditishasMD I swear not all Ioannis out there are bald 👩‍🦲!!

When 2 amazing Ioannis’s from NYC meet #ASH21 , the room lights up! 💡 was a great pleasure meeting you @iannisaifantis1 !!